Platelet rich plasma, platele-rich fibrin (PRF) and concentrated growth factor (CGF) for treatment of periodontal disease

Thanabalen P, Atikah S, Nurkhodrulnada ML, Roza S, Izzuna MMG
Record ID 32018005469
English
Authors' objectives: To assess the effectiveness, safety and cost-effectiveness of platelet rich plasma (PRP), platelet – rich fibrin (PRF) and concentrated growth factor (CGF) for periodontal therapy
Authors' results and conclusions: PRP, PRF and CGF appeared to be effective in improving in pocket depth (PD) reduction and clinical attachment loss (CAL) gain in the treatment of periodontal therapy. The evidence showed that use of autologous platelet concentrates (APC) as an adjunct for periodontal therapy may bring some advantages in the treatment of infrabony defects especially in open flap debridement and open flap debridement with bone graft. The available studies have poor methodological quality and small sample size. No retrievable evidence on safety and cost-effectiveness of platelet rich plasma (PRP), platelet-rich fibrin (PRF) and concentrated growth factor (CGF) for periodontal therapy. However, cost analysis showed the estimated additional cost associated with PRF or CGF treatment ranged from RM62 to RM 68 per patient per year. A decrease by at least one outpatient visit would yield an estimate of MYR293 of potential cost saving per patient.
Authors' recommendations: PRP, PRF and CGF may be used as an adjunct treatment of infrabony defects in periodontal therapy.
Authors' methods: Literature search was done to search for published articles to assess the effectiveness, safety and cost-effectiveness of platelet rich plasma (PRP), platelet-rich fibrin (PRF) and concentrated growth factor (CGF) for periodontal therapy. The following electronic databases were searched via, OVID: MEDLINE (1946 to 03 March 2021), EBM Reviews-Cochrane Database of Systematic Reviews (2005 to September 29, 2021), EBM Reviews–Cochrane Clinical Answers (September 2021), EBM Reviews–Database of Abstracts of Review of Effects (1st Quarter 2016), EBM Reviews–Health Technology Assessment (4th Quarter 2016), NHS economic evaluation database (1st Quarter 2016), PubMed and INAHTA database. The last search was run on 03 March 2021.
Authors' identified further research: -
Details
Project Status: Completed
Year Published: 2021
URL for published report: https://www.moh.gov.my/index.php/database_stores/store_view_page/30/378
Requestor: Ministry of health
English language abstract: An English language summary is available
Publication Type: Mini HTA
Country: Malaysia
MeSH Terms
  • Platelet-Rich Plasma
  • Platelet-Rich Fibrin
  • Periodontal Diseases
  • Intercellular Signaling Peptides and Proteins
  • Surgery, Oral
Keywords
  • Platelet rich plasma
  • Plateket fibrin
  • Concentrated growth factor
  • Periodontal
Contact
Organisation Name: Malaysian Health Technology Assessment
Contact Address: Malaysian Health Technology Assessment Section, Ministry of Health Malaysia, Federal Government Administrative Centre, Level 4, Block E1, Parcel E, 62590 Putrajaya Malaysia Tel: +603 8883 1229
Contact Name: htamalaysia@moh.gov.my
Contact Email: htamalaysia@moh.gov.my
Copyright: Malaysian Health Technology Assessment Section (MaHTAS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.